title: [Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
abstract: Beside the typical extrapyramidal motor symptoms such as rigidity, tremor, and dyskinesia, a reduction in handwriting area may occur under neuroleptic therapy. To date, the nature of the relationship between a reduction in handwriting area and striatal D2 dopamine receptor occupancy has remained unclear, and it is not known whether such a reduction also occurs under treatment with atypical neuroleptic drugs. In 23 schizophrenic patients treated with haloperidol, haloperidol decanoate, risperidone, and clozapine, the handwriting are was examined using a planimetric computer program. 123I-iodobenzamide (IBZM) single photon emission tomography (SPET) was used to measure the D2 dopamine receptor occupancy. A statistically significant correlation was found between a reduction in handwriting area and D2 dopamine receptor occupancy (r = 0.86; P < 0.0001). The curve derived from the plotted data resulted in a hyperbolic function. The regression was present regardless of whether the patients were treated with typical or atypical neuroleptic drugs.
authors.affiliation: Klinik und Poliklinik für Psychiatrie, Universität Leipzig.
authors.forename: U
authors.initials: U
authors.lastname: Künstler
authors.forename: K
authors.initials: K
authors.lastname: Hohdorf
authors.forename: R
authors.initials: R
authors.lastname: Regenthal
authors.forename: A
authors.initials: A
authors.lastname: Seese
authors.forename: H J
authors.initials: HJ
authors.lastname: Gertz
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D003024:Clozapine / Q000627:therapeutic use; D018492:Dopamine Antagonists; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006236:Handwriting; D006801:Humans; D008297:Male; D008875:Middle Aged; D017072:Neostriatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D011759:Pyrrolidines; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism; D018967:Risperidone / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D013810:Therapeutic Equivalency; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D018492:Dopamine Antagonists; D011759:Pyrrolidines; D011954:Receptors, Dopamine; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone